DK1401837T3 - Purinderivater som A2B-adenosinreceptorantagonister - Google Patents

Purinderivater som A2B-adenosinreceptorantagonister

Info

Publication number
DK1401837T3
DK1401837T3 DK02749704T DK02749704T DK1401837T3 DK 1401837 T3 DK1401837 T3 DK 1401837T3 DK 02749704 T DK02749704 T DK 02749704T DK 02749704 T DK02749704 T DK 02749704T DK 1401837 T3 DK1401837 T3 DK 1401837T3
Authority
DK
Denmark
Prior art keywords
optionally substituted
receptor antagonists
adenosine receptor
purine derivatives
sup
Prior art date
Application number
DK02749704T
Other languages
English (en)
Inventor
Jeff A Zablocki
Venkata Palle
Vaibhav Varkhedkar
Dengming Xiao
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1401837T3 publication Critical patent/DK1401837T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK02749704T 2001-06-29 2002-06-27 Purinderivater som A2B-adenosinreceptorantagonister DK1401837T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30220801P 2001-06-29 2001-06-29

Publications (1)

Publication Number Publication Date
DK1401837T3 true DK1401837T3 (da) 2005-11-07

Family

ID=23166757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02749704T DK1401837T3 (da) 2001-06-29 2002-06-27 Purinderivater som A2B-adenosinreceptorantagonister

Country Status (10)

Country Link
US (2) US6770651B2 (da)
EP (1) EP1401837B1 (da)
JP (1) JP4335000B2 (da)
KR (2) KR100897219B1 (da)
AT (1) ATE307132T1 (da)
CA (1) CA2451244C (da)
DE (1) DE60206756T2 (da)
DK (1) DK1401837T3 (da)
ES (1) ES2247356T3 (da)
WO (1) WO2003002566A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
ES2279903T3 (es) * 2001-12-18 2007-09-01 Cv Therapeutics, Inc. Antagonistas del receptor a2a de adenosina.
DE60322748D1 (de) * 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
NL1023355C2 (nl) * 2003-05-07 2004-11-09 Oce Tech Bv Hot melt inkt omvattend een mengsel van kleurstoffen.
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2005009445A1 (en) * 2003-07-22 2005-02-03 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
WO2005047268A2 (en) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
WO2005058898A2 (en) * 2003-12-16 2005-06-30 Ranbaxy Laboratories Limited Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
KR101334511B1 (ko) 2004-12-30 2013-11-29 아스텍스 테라퓨틱스 리미티드 Ｃｄｋ, ｇｓｋ 및 오로라 키나아제의 활성을 조절하는피라졸 화합물
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
JP2009504803A (ja) 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
EP2029597A4 (en) * 2006-05-31 2011-11-23 Univ California purine analogs
EP2049119A2 (en) 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
US7470697B2 (en) * 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
WO2009052310A1 (en) * 2007-10-16 2009-04-23 Cv Therapeutics, Inc A3 adenosine receptor antagonists
JP2011511073A (ja) * 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
EP2268641B1 (en) 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
WO2010009194A1 (en) * 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
WO2010093436A2 (en) * 2009-02-11 2010-08-19 Carson Dennis A Toll-like receptor modulators and treatment of diseases
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
HUE025704T2 (en) * 2009-03-20 2016-04-28 Sigma Tau Ind Farmaceuti Oxidized triazolyl purine derivatives used as adenosine A2A receptor ligands and their use as medicaments
US8796290B2 (en) 2009-11-09 2014-08-05 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
BR112012032766A2 (pt) 2010-06-30 2019-09-24 Gilead Sciences Inc uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
AU2011303420B2 (en) 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
EP3226861A2 (en) * 2014-12-05 2017-10-11 Centre National de la Recherche Scientifique (CNRS) Compounds for treating cystic fibrosis
WO2017188287A1 (ja) * 2016-04-26 2017-11-02 大日本住友製薬株式会社 置換プリン誘導体
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
MX2021010701A (es) * 2019-03-05 2022-02-21 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad.
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
AU760071B2 (en) 1999-08-31 2003-05-08 Vanderbilt University Selective antagonists of A2B adenosine receptors
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
ES2279903T3 (es) * 2001-12-18 2007-09-01 Cv Therapeutics, Inc. Antagonistas del receptor a2a de adenosina.

Also Published As

Publication number Publication date
CA2451244A1 (en) 2003-01-09
KR20040023634A (ko) 2004-03-18
EP1401837B1 (en) 2005-10-19
HK1064096A1 (en) 2005-01-21
US7238700B2 (en) 2007-07-03
DE60206756T2 (de) 2006-07-13
US20030064999A1 (en) 2003-04-03
KR100883292B1 (ko) 2009-02-11
EP1401837A1 (en) 2004-03-31
WO2003002566A1 (en) 2003-01-09
ATE307132T1 (de) 2005-11-15
JP2004536102A (ja) 2004-12-02
US6770651B2 (en) 2004-08-03
ES2247356T3 (es) 2006-03-01
KR20080081208A (ko) 2008-09-08
JP4335000B2 (ja) 2009-09-30
US20040209899A1 (en) 2004-10-21
KR100897219B1 (ko) 2009-05-14
DE60206756D1 (de) 2006-03-02
CA2451244C (en) 2012-01-17

Similar Documents

Publication Publication Date Title
DE60206756D1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
TR200200985T2 (tr) Pürin türevleri
CY1117132T1 (el) Παραγωγο θειαζολιου
MXPA04003795A (es) Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos.
EA200600333A1 (ru) Производные индазола
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
TW200740758A (en) Benzoquinazoline derivatives
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
WO2004069133A3 (en) N-monoacylated o-phenylenediamines as anti -cancer agents
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
NO20033145L (no) Purinderivater som purinergiske reseptorantagonister
DK0784054T3 (da) 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
WO2003022219A3 (en) Biarylamino purine antiproliferative agents
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
PE20050896A1 (es) Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
WO2003068776A1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
EA200400545A1 (ru) Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
NO20090332L (no) 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica